Ignite Creation Date:
2024-05-05 @ 5:18 PM
Last Modification Date:
2024-10-26 @ 9:30 AM
Study NCT ID:
NCT00425542
Status:
COMPLETED
Last Update Posted:
2010-06-11
First Post:
2007-01-22
Brief Title:
Safety Study of Outpatient Treatment for Pulmonary Embolism
Sponsor:
University of Lausanne Hospitals
Organization:
University of Lausanne Hospitals
Study Overview
Official Title:
Outpatient Treatment of Low-risk Patients With Pulmonary Embolism a Randomized-controlled Trial
Status:
COMPLETED
Status Verified Date:
2009-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
OTPE
Brief Summary:
The purpose of this randomized clinical trial is to determine whether outpatient treatment is as effective and safe as inpatient treatment among low-risk patients with pulmonary embolism
Detailed Description:
Pulmonary embolism PE is a worldwide health problem with an estimated incidence of up to 69 cases per 100000 persons annually In the US 101000 patients were hospitalized with a primary diagnosis of PE in 2002 resulting in direct medical costs of 720 million There is growing evidence that outpatient treatment with low-molecular-weight heparin LMWH is an effective and safe option for up to 50 of patients with non-massive PE Despite this evidence outpatient treatment of PE is uncommon because 1 explicit criteria that identify patients who are at low-risk of adverse medical outcomes have not been available and 2 randomized trials demonstrating the effectiveness and safety of outpatient treatment have not been performed We developed a clinical prognostic model that accurately identifies patients with PE who are at low-risk for short-term mortality symptomatic recurrent venous thromboembolism VTE and major bleeding This model provides clinicians an easily applied explicit risk stratification tool for patients with PE addressing a key barrier to outpatient treatment The broad objective of this clinical trial is to address the other major barrier to outpatient treatment of low-risk patients with non-massive PE the effectiveness and safety of outpatient management We will randomize low-risk patients identified using our prognostic model with PE from hospital emergency departments to receive outpatient or inpatient treatment with LMWH for 5 days followed by oral anticoagulation The specific aims of the project are to compare 1 the frequency of recurrent VTE 2 the frequency of major bleeding and all-cause mortality and 3 medical resource utilization and patient satisfaction with care among patients randomized to receive outpatient or inpatient treatment with LMWH The primary study outcome will be the rate of symptomatic recurrent VTE at 3 months after randomization The secondary outcomes will be the rate of major bleeding and all-cause mortality The ancillary outcomes will be medical resource utilization and patient satisfaction with care The hypotheses guiding this trial are that outpatient treatment with LMWH is as effective and safe as inpatient treatment with LMWH and is also associated with reduced medical resource utilization and increase patient satisfaction with care This study is innovative because it translates a validated prognostic model into clinical practice and represents the first direct comparison of outpatient versus inpatient treatment of low-risk patients with PE Successful completion of this project will provide a strong scientific basis for treating low-risk patients with PE in the outpatient setting Outpatient management of low-risk patients with PE is likely to improve quality and efficiency of care by reducing resource utilization and increasing patient satisfaction with care Our findings will have importance to physicians hospitals and policy-makers who are committed to optimizing patient safety and providing high-quality cost-effective care
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 1R01HL085565-01A2 | NIH | None | httpsreporternihgovquickSearch1R01HL085565-01A2 |